Show simple item record

dc.contributor.authorBarker, Roger
dc.contributor.authorMason, Sarah
dc.date.accessioned2019-01-08T00:30:45Z
dc.date.available2019-01-08T00:30:45Z
dc.date.issued2019-02
dc.identifier.issn1474-4422
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/287598
dc.description.abstractHuntington’s Disease (HD) is an autosomal dominant condition that typically presents in midlife with a combination of motor, cognitive and psychiatric problems along with sleep and metabolic abnormalities. It runs a clinical course over 15-20 years leading to death as patients become demented and bed bound. There are currently no proven disease modifying therapies for HD. While the recent work with anti-sense therapies (ASO) against huntingtin has generated much excitement they are yet to demonstrate a measurable change in disease progression. Furthermore, given they promise to “modify” and not “cure” HD patients we will still require adjunct symptomatic treatments, potentially for longer periods of time. Symptomatic therapies for HD do exist and are widely used for treating the chorea and some of the psychiatric aspects of the condition although the extent to which they work is variable1 and many experience significant side effects with them. Therefore, there is still a need to develop better symptomatic therapies, ideally with single drugs that can help treat more than one sign and symptom of this condition.
dc.format.mediumPrint-Electronic
dc.languageeng
dc.publisherElsevier BV
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectHumans
dc.subjectHuntington Disease
dc.subjectPiperidines
dc.titleThe hunt for better treatments for Huntington's disease.
dc.typeArticle
prism.endingPage133
prism.issueIdentifier2
prism.publicationDate2019
prism.publicationNameLancet Neurol
prism.startingPage131
prism.volume18
dc.identifier.doi10.17863/CAM.34911
dcterms.dateAccepted2018-11-07
rioxxterms.versionofrecord10.1016/S1474-4422(18)30448-4
rioxxterms.versionAM
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2019-02
dc.contributor.orcidBarker, Roger [0000-0001-8843-7730]
dc.contributor.orcidMason, Sarah [0000-0001-6715-4109]
dc.identifier.eissn1474-4465
rioxxterms.typeJournal Article/Review
pubs.funder-project-idCambridge University Hospitals NHS Foundation Trust (CUH) (146281)
pubs.funder-project-idHuntington's Disease Association of England and Wales (HD Economics)
rioxxterms.freetoread.startdate2019-06-14


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's licence is described as Attribution-NonCommercial-NoDerivatives 4.0 International